Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study.
Chemo-immunotherapy
Follicular lymphoma (FL)
Induction
Obinutuzumab
Rituximab
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
03
03
2023
accepted:
29
05
2023
medline:
17
7
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
ppublish
Résumé
The GALLIUM study showed a progression-free survival advantage of 7% in favor of obinutuzumab vs. rituximab-based immunochemotherapies as first-line therapy in follicular lymphoma (FL) patients. Yet, the toxicity appears to be increased with obinutuzumab-based therapy. This is a multicenter retrospective-cohort study including adult FL patients comparing the toxicity of first-line rituximab vs. obinutuzumab-based chemo-immunotherapies (R and O groups, respectively). We compared the best standard-of-care therapy used per time period, before and after obinutuzumab approval. The primary outcome was any infection during induction and 6 months post-induction. Secondary outcomes included rates of febrile neutropenia, severe and fatal infections, other adverse events, and all-cause mortality. Outcomes were compared between groups. A total of 156 patients were included in the analysis, 78 patients per group. Most patients received bendamustine (59%) or CHOP (31.4%) as adjacent chemotherapy. Half of the patients received growth-factor prophylaxis. Overall, 69 patients (44.2%) experienced infections, and a total of 106 infectious episodes were recorded. Patients in the R and O groups had similar rates of any infection (44.8% and 43.5%, p = 1), severe infections (43.3% vs. 47.8%, p = 0.844), febrile neutropenia (15% vs. 19.6%, p = 0.606), and treatment discontinuation, as well as similar types of infections. No covariate was associated with infection in multivariable analysis. No statistically significant difference was evident in adverse events of grades 3-5 (76.9% vs. 82%, p = 0.427). To conclude, in this largest real-life study of first-line treated FL patients comparing R- to O-based therapy, we did not observe any difference in toxicity during the induction and 6 months post-induction period.
Identifiants
pubmed: 37335322
doi: 10.1007/s00277-023-05306-2
pii: 10.1007/s00277-023-05306-2
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
obinutuzumab
O43472U9X8
Bendamustine Hydrochloride
981Y8SX18M
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2127-2136Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Teras LR, DeSantis CE, Cerhan JR et al (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443–459. https://doi.org/10.3322/caac.21357
doi: 10.3322/caac.21357
pubmed: 27618563
Dotan E, Aggarwal C, Smith MR (2010) Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin’s lymphoma. P T 35:148–157
pubmed: 20442809
pmcid: 2844047
Schulz H, Bohlius JF, Trelle S et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99:706–714. https://doi.org/10.1093/jnci/djk152
doi: 10.1093/jnci/djk152
pubmed: 17470738
Marcus R, Davies A, Ando K et al (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377:1331–1344. https://doi.org/10.1056/NEJMoa1614598
doi: 10.1056/NEJMoa1614598
pubmed: 28976863
Townsend W, Buske C, Cartron G et al (2020) Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: updated results from the phase III Gallium Study. JCO 38:8023–8023. https://doi.org/10.1200/JCO.2020.38.15_suppl.8023
doi: 10.1200/JCO.2020.38.15_suppl.8023
McNamara C, Montoto S, Eyre TA et al (2020) The investigation and management of follicular lymphoma. Br J Haematol 191:363–381. https://doi.org/10.1111/bjh.16872
doi: 10.1111/bjh.16872
pubmed: 32579717
Dreyling M, Ghielmini M, Rule S et al (2021) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32:298–308. https://doi.org/10.1016/j.annonc.2020.11.008
doi: 10.1016/j.annonc.2020.11.008
pubmed: 33249059
Gafter-Gvili A, Ribakovsky E, Mizrahi N et al (2016) Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. Leuk Lymphoma 57:63–69. https://doi.org/10.3109/10428194.2015.1046862
doi: 10.3109/10428194.2015.1046862
pubmed: 25944378
Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309–332. https://doi.org/10.1016/j.ajic.2008.03.002
doi: 10.1016/j.ajic.2008.03.002
pubmed: 18538699
Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56-93. https://doi.org/10.1093/cid/cir073
doi: 10.1093/cid/cir073
pubmed: 21258094
Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE – version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo-Sifiliográficas (English Edition) 112:90–92. https://doi.org/10.1016/j.adengl.2019.05.021
doi: 10.1016/j.adengl.2019.05.021
Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068. https://doi.org/10.1200/JCO.2013.54.8800
doi: 10.1200/JCO.2013.54.8800
pubmed: 25113753
pmcid: 4979083
Claustre G, Boulanger C, Maloisel F et al (2022) Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-022-04155-2
doi: 10.1007/s00432-022-04155-2
pubmed: 35789429
pmcid: 9255466
Amitai I, Gafter-Gvili A, Shargian-Alon L et al (2021) Obinutuzumab-related adverse events: a systematic review and meta-analysis. Hematol Oncol 39:215–221. https://doi.org/10.1002/hon.2828
doi: 10.1002/hon.2828
pubmed: 33252145
Shimony S, Bar-Sever E, Berger T et al (2021) Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity. Leuk Lymphoma 62:2921–2927. https://doi.org/10.1080/10428194.2021.1948037
doi: 10.1080/10428194.2021.1948037
pubmed: 34284690
Pfreundschuh M, Müller C, Zeynalova S et al (2014) Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 123:640–646. https://doi.org/10.1182/blood-2013-07-517037
doi: 10.1182/blood-2013-07-517037
pubmed: 24297867
Horesh N, Horowitz NA (2014) Does gender matter in non-hodgkin lymphoma? Differences in epidemiology, clinical behavior, and therapy. Rambam Maimonides Med J 5:e0038. https://doi.org/10.5041/RMMJ.10172
doi: 10.5041/RMMJ.10172
pubmed: 25386354
pmcid: 4222427
Cartron G, Hourcade-Potelleret F, Morschhauser F et al (2016) Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. Haematologica 101:226–234. https://doi.org/10.3324/haematol.2015.133421
doi: 10.3324/haematol.2015.133421
pubmed: 26659915
pmcid: 4938339
Yıldız A, Albayrak M, Pala Ç et al (2018) Infections in patients with lymphoma: an analysis of incidence, relationship and risk factors. J Infect Dev Ctries 12:741–747. https://doi.org/10.3855/jidc.10399
doi: 10.3855/jidc.10399
pubmed: 31999632
Gafter-Gvili A, Gurion R, Raanani P et al (2017) Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials. Hematol Oncol 35:424–431. https://doi.org/10.1002/hon.2350
doi: 10.1002/hon.2350
pubmed: 27734524
Anaissie EJ, Kontoyiannis DP, O’Brien S et al (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129:559–566. https://doi.org/10.7326/0003-4819-129-7-199810010-00010
doi: 10.7326/0003-4819-129-7-199810010-00010
pubmed: 9758577
Hensel M, Kornacker M, Yammeni S et al (2003) Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol 122:600–606. https://doi.org/10.1046/j.1365-2141.2003.04497.x
doi: 10.1046/j.1365-2141.2003.04497.x
pubmed: 12899715
Solal-Céligny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265. https://doi.org/10.1182/blood-2003-12-4434
doi: 10.1182/blood-2003-12-4434
pubmed: 15126323
Levy I, Lavi A, Zimran E et al (2021) COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. Leuk Lymphoma 62:3384–3393. https://doi.org/10.1080/10428194.2021.1966782
doi: 10.1080/10428194.2021.1966782
pubmed: 34405767
Visco C, Marcheselli L, Mina R et al (2022) A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv 6:327–338. https://doi.org/10.1182/bloodadvances.2021005691
doi: 10.1182/bloodadvances.2021005691
pubmed: 34644385
pmcid: 8516438
García-Suárez J, de la Cruz J, Cedillo Á et al (2020) Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol 13:133. https://doi.org/10.1186/s13045-020-00970-7
doi: 10.1186/s13045-020-00970-7
pubmed: 33032660
pmcid: 7542567
Tvito A, Ronson A, Ghosheh R et al (2022) Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment. Exp Hematol 107:20–23. https://doi.org/10.1016/j.exphem.2021.12.396
doi: 10.1016/j.exphem.2021.12.396
pubmed: 34952139
Gurion R, Rozovski U, Itchaki G et al (2022) Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica 107:715–720. https://doi.org/10.3324/haematol.2021.279216
doi: 10.3324/haematol.2021.279216
pubmed: 34320790